Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the effects of the anti-TNF-α monoclonal antibody golimumab, administered by s.c. injection or i.v. infusion, on markers of inflammation in patients with RA. METHODS: In this phase 1, open-label study, patients with active RA were randomized to receive s.c. golimumab 100 mg at baseline and every 4 weeks through week 20 (n = 33; group 1) or i.v. golimumab 2 mg/kg at baseline and week 12 (n = 16; group 2). Serum levels of CRP, IL-6, serum amyloid A (SAA), TNF receptor II (TNFRII), MMP-3, hyaluronic acid, haptoglobin, ferritin and haemoglobin and serum/urine hepcidin were measured at various time points. Associations between the biomarkers were assessed with Spearman's correlations. RESULTS: In both groups 1 and 2, decreases in mean serum levels of CRP, IL-6, SAA, TNFRII, MMP-3, haptoglobin, ferritin and hepcidin, and mean urine levels of hepcidin occurred within 1 week and were sustained through week 8. Decreases in concentrations of serum CRP, IL-6, SAA, MMP-3, hepcidin, ferritin and haptoglobin and urine hepcidin were maintained through week 24 in group 1, but began to reverse after week 8 in group 2. Among all patients, decreases in serum hepcidin correlated significantly with decreases in serum CRP and ferritin. CONCLUSION: Decreases in serum and urine concentrations of markers of inflammation occurred as early as 24 h after treatment with golimumab, and most of these improvements were sustained through week 24 in group 1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar results were obtained when rheumatoid arthritis patients were treated with antibodies against TNFα (golimumab or infliximab), possibly as an indirect result of concomitant suppression of IL-6 (Doyle et al., 2013; Song et al., 2013).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Doyle et al., 2013
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
Nicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B., Kahn, A., & Vaulont, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151179498 · Cited by 1,233
Severe iron deficiency anemia in transgenic mice expressing liver hepcidin
Nicolas, G., Bennoun, M., Porteu, A., Mativet, S., Beaumont, C., Grandchamp, B., Sirito, M., Sawadogo, M., Kahn, A., & Vaulont, S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072632499 · Cited by 880
Immunoassay for human serum hepcidin
Ganz, T., Olbina, G., Girelli, D., Nemeth, E., & Westerman, M. (2008) · Blood · doi:10.1182/blood-2008-02-139915 · Cited by 688
Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S. T., Miranda, P. C., Pazdur, J., Bae, S.-C., Palmer, W., Zrubek, J., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099010 · Cited by 541
Smolen, J. S., Kay, J., Doyle, M. K., Landewé, R., Matteson, E. L., Wollenhaupt, J., Gaylis, N., Murphy, F. T., Neal, J. S., Zhou, Y., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60506-7 · Cited by 526
Emery, P., Fleischmann, R. M., Moreland, L. W., Hsia, E. C., Strusberg, I., Durez, P., Nash, P., Amante, E. J. B., Churchill, M., Park, W., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24638 · Cited by 398
Impact of Anemia on Mortality, Cognition, and Function in Community-Dwelling Elderly
Denny, S. D., Kuchibhatla, M. N., & Cohen, H. J. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.08.027 · Cited by 345
Research works printed but not linked: 1
- van Riel, 2000, EULAR handbook of clinical assessments in rheumatoid arthritis
Cited by
Zhou, Q., Jin, J.-F., Zhu, L.-L., Chen, M., Xu, H.-M., Wang, H.-F., Feng, X.-Q., & Zhu, X.-P. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s87271 · Cited by 296
“Decreases in concentrations of these inflammatory markers were maintained through week 24 in SC group but began to reverse after week 8 in IV group, indicating that SC route was superior to IV route in golimumab treatment of rheumatoid arthritis.(17) Sylwestrzak et al examined patient preferences regarding available a…”
Alcayaga-Miranda, F., Cuenca, J., & Khoury, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00339 · Cited by 296
Pharmacological Targeting of the Hepcidin/Ferroportin Axis
Sebastiani, G., Wilkinson, N., & Pantopoulos, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00160 · Cited by 127
The pathophysiology and pharmacology of hepcidin
Ruchala, P., & Nemeth, E. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.004 · Cited by 140
“Similarly, administration of anti-TNFα antibody decreased hepcidin levels in patients with rheumatoid arthritis [62].”
BackgroundSerum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker
Hosman, I. S., Kos, I., & Lamot, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.631299 · Cited by 154
Metadata
- Authors
- Doyle, M. K., Rahman, M. U., Frederick, B., Birbara, C. A., de Vries, D., Toedter, G., Wu, X., Chen, D., Ranganath, V. K., Westerman, M. E., & Furst, D. E.
- Affiliations
- Janssen Research & Development (United States) (US)
- University of California, Los Angeles (US)
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-14
- Volume
- 52
- Issue
- 7
- Pages
- 1214-1219
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2120116963
- Cited by
- 40
- References
- 25
- Citations by year
- 2024: 3 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 8 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 1
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lara D. Veeken (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Genentech
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- golimumab, rheumatoid arthritis, anti-TNF monoclonal antibody, subcutaneous administration, intravenous infusion, inflammatory markers, C-reactive protein, interleukin-6, serum amyloid A, TNF receptor 2, matrix metalloproteinase-3, hepcidin, ferritin, haptoglobin, hyaluronic acid, treatment response
- MeSH terms
- Adult, Antibodies, Monoclonal, Arthritis, Rheumatoid, C-Reactive Protein, Ferritins, Humans, Inflammation, Injections, Intravenous, Injections, Subcutaneous, Tumor Necrosis Factor-alpha, Biomarkers, Interleukin-6, Treatment Outcome, Matrix Metalloproteinase 3, Antimicrobial Cationic Peptides, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. https://app.cochat.ai/papers/10.1093/rheumatology/kes381
- The paper
- Doyle, M. K., Rahman, M. U., Frederick, B., Birbara, C. A., de Vries, D., Toedter, G., Wu, X., Chen, D., Ranganath, V. K., Westerman, M. E., & Furst, D. E. (2013). Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology. https://doi.org/10.1093/rheumatology/kes381
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.